01.11.2012
- Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators...
22.12.2011
- Three of Europe's biggest drugmakers - AstraZeneca, Novartis and Sanofi - reported product setbacks, underlining the difficulties of developing new medicines to make up for those...
